Related Experiment Video
Updated: Oct 12, 2025
10:09
Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
3.4K
Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial
Journal of Neurosurgery
|November 19, 2021
Summary
Glibenclamide did not improve functional outcomes or reduce mortality in patients with aneurysmal subarachnoid hemorrhage (aSAH). The study found no significant benefits, with a higher incidence of hypoglycemia in the glibenclamide group.
Area of Science:
- Neurology
- Neurosurgery
- Pharmacology
Background:
- Glibenclamide has shown promise in treating cerebral ischemia and traumatic brain injury.
- Aneurysmal subarachnoid hemorrhage (aSAH) presents significant risks for mortality and poor functional outcomes.
Purpose of the Study:
- To evaluate the efficacy of glibenclamide in improving mortality and functional outcomes for patients diagnosed with aneurysmal subarachnoid hemorrhage (aSAH).
Main Methods:
- A randomized, placebo-controlled trial involving 78 patients with confirmed aSAH.
- Patients received either oral glibenclamide (5 mg daily for 21 days) or a placebo.
- Outcomes, including mortality and functional status (modified Rankin Scale), were assessed at discharge and 6 months.
Main Results:
- Glibenclamide did not significantly improve 6-month functional outcomes (mRS) compared to placebo.
- No significant differences were observed in mortality, delayed cerebral ischemia, or discharge functional status.
- Hypoglycemia occurred more frequently in the glibenclamide group (5.3%).
Conclusions:
- Glibenclamide treatment was not associated with improved functional outcomes in patients following aSAH.
- The drug did not reduce mortality or the incidence of delayed cerebral ischemia in this patient cohort.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
799
11:58Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
Published on: August 11, 2015
15.7K
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
301
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
301
01:23Dipeptidyl Peptidase 4 Inhibitors
289
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
289
01:28Angle Closure Glaucoma: Treatment
886
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
886
01:27Open Angle Glaucoma: Treatment
748
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
748
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
314
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
314
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
46
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
46